The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy.

To evaluate whether bilateral prostate cancer detected at Active Surveillance (AS) enrollment is associated with progression to Grade Group ≥2 (GG2) and to compare the efficacy of combined targeted biopsy plus systematic biopsy (CBx) versus systematic biopsy (Sbx) or targeted biopsy (Tbx) alone to detect bilateral disease.